메뉴 건너뛰기




Volumn 8, Issue , 2010, Pages

Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 5 MONOCLONAL ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY CD40; RECOMBINANT INTERLEUKIN 2; TRIPLE MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; INTERLEUKIN 2;

EID: 77951601276     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-42     Document Type: Article
Times cited : (23)

References (25)
  • 1
    • 0030892234 scopus 로고    scopus 로고
    • Apoptosis by death factor
    • 10.1016/S0092-8674(00)81874-7, 9039262
    • Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365. 10.1016/S0092-8674(00)81874-7, 9039262.
    • (1997) Cell , vol.88 , pp. 355-365
    • Nagata, S.1
  • 3
    • 0032896709 scopus 로고    scopus 로고
    • CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
    • 10.1038/5505, 10229232
    • French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999, 5:548-553. 10.1038/5505, 10229232.
    • (1999) Nat Med , vol.5 , pp. 548-553
    • French, R.R.1    Chan, H.T.2    Tutt, A.L.3    Glennie, M.J.4
  • 4
    • 0344247505 scopus 로고
    • CDNA sequences of two inducible T-cell genes
    • 10.1073/pnas.86.6.1963, 286825, 2784565
    • Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989, 86:1963-1967. 10.1073/pnas.86.6.1963, 286825, 2784565.
    • (1989) Proc Natl Acad Sci USA , vol.86 , pp. 1963-1967
    • Kwon, B.S.1    Weissman, S.M.2
  • 5
    • 0033137063 scopus 로고    scopus 로고
    • Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal
    • Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999, 162:5037-5040.
    • (1999) J Immunol , vol.162 , pp. 5037-5040
    • Takahashi, C.1    Mittler, R.S.2    Vella, A.T.3
  • 6
    • 0037094139 scopus 로고    scopus 로고
    • 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function
    • Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002, 168:4897-4906.
    • (2002) J Immunol , vol.168 , pp. 4897-4906
    • Wen, T.1    Bukczynski, J.2    Watts, T.H.3
  • 9
    • 45649084324 scopus 로고    scopus 로고
    • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
    • 10.1016/j.lungcan.2007.12.011, 18255187
    • Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90. 10.1016/j.lungcan.2007.12.011, 18255187.
    • (2008) Lung Cancer , vol.61 , pp. 82-90
    • Greco, F.A.1    Bonomi, P.2    Crawford, J.3    Kelly, K.4    Oh, Y.5    Halpern, W.6    Lo, L.7    Gallant, G.8    Klein, J.9
  • 10
    • 50349092260 scopus 로고    scopus 로고
    • A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
    • 10.1158/1078-0432.CCR-07-1416, 18519776
    • Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:3450-3455. 10.1158/1078-0432.CCR-07-1416, 18519776.
    • (2008) Clin Cancer Res , vol.14 , pp. 3450-3455
    • Hotte, S.J.1    Hirte, H.W.2    Chen, E.X.3    Siu, L.L.4    Le, L.H.5    Corey, A.6    Iacobucci, A.7    MacLean, M.8    Lo, L.9    Fox, N.L.10    Oza, A.M.11
  • 11
    • 69949110775 scopus 로고    scopus 로고
    • Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study
    • 10.1158/1078-0432.CCR-09-0996, 19690193
    • Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009, 15:5584-5590. 10.1158/1078-0432.CCR-09-0996, 19690193.
    • (2009) Clin Cancer Res , vol.15 , pp. 5584-5590
    • Mom, C.H.1    Verweij, J.2    Oldenhuis, C.N.3    Gietema, J.A.4    Fox, N.L.5    Miceli, R.6    Eskens, F.A.7    Loos, W.J.8    de Vries, E.G.9    Sleijfer, S.10
  • 12
    • 70349318434 scopus 로고    scopus 로고
    • Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
    • Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, et al. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. J Clin Oncol 2009,
    • (2009) J Clin Oncol
    • Leong, S.1    Cohen, R.B.2    Gustafson, D.L.3    Langer, C.J.4    Camidge, D.R.5    Padavic, K.6    Gore, L.7    Smith, M.8    Chow, L.Q.9    von Mehren, M.10
  • 17
    • 68149132103 scopus 로고    scopus 로고
    • CD1d-based combination therapy eradicates established tumors in mice
    • 10.4049/jimmunol.0900796, 19620318
    • Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ. CD1d-based combination therapy eradicates established tumors in mice. J Immunol 2009, 183:1911-1920. 10.4049/jimmunol.0900796, 19620318.
    • (2009) J Immunol , vol.183 , pp. 1911-1920
    • Teng, M.W.1    Sharkey, J.2    McLaughlin, N.M.3    Exley, M.A.4    Smyth, M.J.5
  • 18
    • 70349170354 scopus 로고    scopus 로고
    • Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth
    • 10.1371/journal.pone.0006982, 2734989, 19746156
    • Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009, 4:e6982. 10.1371/journal.pone.0006982, 2734989, 19746156.
    • (2009) PLoS One , vol.4
    • Most, R.G.1    Currie, A.J.2    Cleaver, A.L.3    Salmons, J.4    Nowak, A.K.5    Mahendran, S.6    Larma, I.7    Prosser, A.8    Robinson, B.W.9    Smyth, M.J.10
  • 22
    • 0022473607 scopus 로고
    • A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
    • 10.1126/science.3489291, 3489291
    • Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321. 10.1126/science.3489291, 3489291.
    • (1986) Science , vol.233 , pp. 1318-1321
    • Rosenberg, S.A.1    Spiess, P.2    Lafreniere, R.3
  • 24
    • 0026033391 scopus 로고
    • Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo
    • 10.1002/eji.1830210350, 2009918
    • Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991, 21:851-854. 10.1002/eji.1830210350, 2009918.
    • (1991) Eur J Immunol , vol.21 , pp. 851-854
    • Ley, V.1    Langlade-Demoyen, P.2    Kourilsky, P.3    Larsson-Sciard, E.L.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.